AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Mount Yale Investment Advisors LLC

Mount Yale Investment Advisors LLC cut its stake in AstraZeneca PLC (NASDAQ:AZN) by 6.6% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 44,653 shares of the company’s stock after selling 3,162 shares during the period. Mount Yale Investment Advisors LLC’s holdings in AstraZeneca were worth $2,926,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. AQR Capital Management LLC raised its stake in shares of AstraZeneca by 112.4% in the second quarter. AQR Capital Management LLC now owns 13,685 shares of the company’s stock worth $1,067,000 after purchasing an additional 7,241 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in AstraZeneca by 39.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 206,446 shares of the company’s stock worth $16,104,000 after buying an additional 58,039 shares during the last quarter. Mackenzie Financial Corp lifted its stake in AstraZeneca by 9.3% during the 2nd quarter. Mackenzie Financial Corp now owns 307,954 shares of the company’s stock valued at $24,017,000 after acquiring an additional 26,213 shares during the period. Scientech Research LLC purchased a new stake in shares of AstraZeneca in the 2nd quarter valued at $407,000. Finally, Kathmere Capital Management LLC increased its stake in shares of AstraZeneca by 35.3% in the second quarter. Kathmere Capital Management LLC now owns 5,501 shares of the company’s stock worth $429,000 after acquiring an additional 1,436 shares during the period. Hedge funds and other institutional investors own 20.35% of the company’s stock.

AstraZeneca Price Performance

AstraZeneca stock opened at $69.06 on Monday. The stock has a market capitalization of $214.16 billion, a P/E ratio of 33.04, a P/E/G ratio of 1.13 and a beta of 0.46. The company’s fifty day moving average price is $66.44 and its 200 day moving average price is $74.14. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. AstraZeneca PLC has a 1 year low of $60.47 and a 1 year high of $87.68.

AstraZeneca (NASDAQ:AZN) last released its earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. The business had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The company’s quarterly revenue was up 18.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.87 earnings per share. As a group, equities research analysts anticipate that AstraZeneca PLC will post 4.12 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently issued reports on AZN shares. UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.